Tag Archives: DETERx

Weekly medical stock spotlight: Buy, wait or run? Leaders = Otonomy, Collegium & Sage; Laggards = Selecta & Tivity.

1.Otonomy Inc. (Nasdaq:OTIC) led advancing issues last week, rocketing 73% to $5.17. A Phase 3 clinical trial (AVERTS-2) assessing Otonomy’s Otividex in patients with Ménière’s disease, achieved its primary endpoint of the… Read more »